Zeldes & Haeggquist, LLP has commenced an investigation into possible legal claims against the Board of Directors of Life Technologies Corp. (“Life” or “the Company”) (NASDAQ: LIFE). The investigation concerns possible breaches of fiduciary duties and other violations of law related to a sale of the Company to Thermo Fisher Scientific, Inc.  (“Thermo Fisher”) (NYSE: TMO).

Carlsbad-based Life, a global biotechnology company, holds more than 5,000 patents and licenses in scientific exploration, molecular diagnosis, 21st century forensics, regenerative medicine, and agricultural research. On April 15, 2013, Life and Thermo Fisher announced the acquisition–a deal valued at $13.6 billion.

Zeldes & Haeggquist’s investigation concerns whether Life’s Board of Directors failed to adequately shop the Company to obtain the best possible value for its shareholders before entering into an agreement with Thermo Fisher. Under the terms of the proposal, Life shareholders will receive $76 in cash per share.

If you own the common stock of Life and purchased your shares before April 15, 2013, and would like additional information regarding this investigation, or if you have information regarding the matters under investigation, please contact attorney Aaron M. Olsen or Amber L. Eck at 619-342-8000, or by email at aarono@zhlaw.com or ambere@zhlaw.com.